Clinical Trial Detail

NCT ID NCT01809691
Title S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Recruitment Active, not recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors Southwest Oncology Group
Indications

prostate cancer

Therapies

Orteronel

Bicalutamide

Age Groups: adult

No variant requirements are available.